食管癌CARBO联合DDP与5-FU新辅助化疗的疗效分析  

Clinical efficiency study of the combination of carboplatin,cisplation and 5-fluorouracil as neoadjuvant chemotherapy regiment in treatment of esophageal carcinoma

作　　者：任中海[1] 张成辉[1] 金哲[2] 李伟[2] 仝运科[1] 陈天法[1] 

机构地区：[1]南阳市中心医院肿瘤科,河南南阳473000 [2]南阳市中心医院胸外科,河南南阳473000

出　　处：《中华肿瘤防治杂志》2008年第10期785-786,共2页Chinese Journal of Cancer Prevention and Treatment

基　　金：河南省2005年攻关课题(0524410002);河南省科技人才创新工程2004年资助项目(豫卫科[2004]21-89)

摘　　要：为了观察CARBO+DDP+5-FU方案新辅助化疗对N1期食管癌的疗效,对32例入组的N1期食管癌患者应用CPF方案:CARBO300mg/m2,静脉滴入,d1;DDP25mg/m2,静脉滴入,d2～d5;5-FU500mg/m2,静脉滴入,d1～d4。21d为1个周期,治疗2个周期后评价疗效和毒性,所有患者均接受行外科手术治疗。结果:CPF方案的客观有效率为71.9%(23/32);毒副反应主要为恶心、呕吐和骨髓抑制;病理缓解的总有效率为62.3%(20/32)。术后1年生存率为78.1%(25/32);中位生存期为27个月。初步研究结果提示,对于N1期食管癌患者,术前新辅助应用CPF方案是个较好的综合治疗方案,值得进一步探讨。The objective of this study was to evaluate the clinical effects of carboplatin, cisplation and 5-fluorouracil as neoadjuvant chemotherapy regiment in the treatment of stage N1 esophageal carcinoma. Thirty-two cases of stage N1 esophageal cancer patients were treated with CPF regimen chemotherapy. The efficacy and toxicity were evaluated after two cycles according to WHO criteria, and all the patients were treated with surgery after the chemotherapy. The total response rate （CR＋PR） was 71.9% （23/32）. The major side effects were nausea-vomiting and myelosuppression. The pathological response rate was 62.3%（20/32）. The 1-year survival rate was 78. 1% （25/32）. The overall median survival was 27 months. In conclusion, the CPF regimen is a better neoadjuvant chemotherapy regimen for stage N1 esophageal carcinoma. Additional investigation is warranted.

关 键 词：食管肿瘤/药物疗法 顺铂 氟尿嘧啶 卡铂 药物疗法 联合 

分 类 号：R735.1[医药卫生—肿瘤]